Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LANTERN: Phase II trial of LYR-210 in adults with chronic sinusitis
2018-004621-89Phase 2Completed
- Sponsor
- Lyra Therapeutics, Inc.
- Start
- May 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LYR-210 in rhinosinusitis (2 arms), sponsored by Lyra Therapeutics, Inc. Primary endpoint: Primary: Change in nasal blockage/obstruction/congestion score at Week 4. Started May 2019; status: completed.
02
Drugs
LYR-210
03
Conditions
rhinosinusitis
Beyond the preview
Go deeper on 2018-004621-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004621-89.